eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of selective translation regulators as a new class of small molecule therapeutics for cancer. The company's investigational compounds are designed to restore translational control to halt underlying disease mechanisms while preserving healthy physiological processes. eFFECTOR's most advanced program focuses on the development of eFT508. The company has additional selective translation regulator programs currently in discovery and development and maintains global rights to all of its development programs.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
07/24/17	$38,600,000	Series C	AbbVie Biotech Ventures Abingworth Alexandria Real Estate Equities Altitude Life Science Ventures Astellas Venture Management BioMed Ventures Novartis Venture Funds Pfizer Strategic Investments Group Sectoral Asset Management SR One The Column Group US Venture Partners	undisclosed